We have examined the regulation of hepatic growth hormone receptors (GH-R) and serum GH binding proteins (GHBP) in transgenic mice expressing an antagonist of bovine growth hormone (bGH), G119K-bGH, and consequently exhibiting a growth suppressed dwarf phenotype. Specific GHBP could be measured in transgenic dwarf mouse serum only by immunological methods (RIA), because these mice have a very high concentration of mutated bGH in circulation (> 1 microgram/ml) and, therefore, almost all GHBP is bound to G119K-bGH and cannot be quantitated in binding assays. The concentrations of GHBP were 0.6 +/- 0.4 nM and 1.7 +/- 0.4 nM for normal and dwarf mice respectively. The concentrations of free GHBP in normal mice and in transgenic mice expressing wild-type GH can be calculated using chromatographic techniques as the dissociation constant (Kd) and the ratio of bound 125I-GH to free 125I-GH in the serum ([GHBP]free = B/F.Kd). In agreement with the assumption that GHBP reflects GH-R status, liver uptake of injected labeled bGH was greatly reduced in transgenic dwarfs in comparison with normal mice or with transgenic mice expressing wild-type bGH (liver/blood ratio of 0.48 +/- 0.21, 2.7 +/- 0.2, and 1.3 +/- 0.3 respectively) indicating that the high concentration of the mutated bGH (G119K-bGH) prevents labeled bGH uptake, as was expected from the dwarf phenotype. 125I-bGH taken up by the liver of transgenic dwarf mice was found in a smaller molecular species than in normal mice, compatible with the presence of 1:1 [(GH-R):GH] complexes instead of the 2:1 [(GH-R)2:GH] or 2:2 [(GHBP)2:(GH)2] complexes found in normal mice. The concentration of IGF-I, the principal mediator of GH activity, in the G119K-bGH transgenic mice was correlated with the concentration of free GHBP. This allowed us to use free GHBP concentration as a marker of the effects of the active endogenous hormone (mGH) on liver receptors in the presence of different concentrations of the antagonist of GH. The levels of GHBP in serum, as well as the concentration of GH-R in liver microsomes from mice expressing the bGH antagonist, are up-regulated by the high concentration of G119K-bGH (85%), but significantly less so than that which could be expected for the same concentration of native GH (220-275%). This up-regulation suggests that the G119K-bGH antagonist is internalized and induces synthesis of the receptor and of the binding protein.

This article has been cited by other articles:

				J. G Miquet, L. Gonzalez, M. N Matos, C. E Hansen, A. Louis, A. Bartke, D. Turyn, and A. I Sotelo Transgenic mice overexpressing GH exhibit hepatic upregulation of GH-signaling mediators involved in cell proliferation J. Endocrinol., August 1, 2008; 198(2): 317 - 330. [Abstract] [Full Text] [PDF]

				W. Savino Neuroendocrine control of T cell development in mammals: role of growth hormone in modulating thymocyte migration Exp Physiol, September 1, 2007; 92(5): 813 - 817. [Abstract] [Full Text] [PDF]

				S. Smaniotto, V. de Mello-Coelho, D. M. S. Villa-Verde, J.-M. Pleau, M.-C. Postel-Vinay, M. Dardenne, and W. Savino Growth Hormone Modulates Thymocyte Development in Vivo through a Combined Action of Laminin and CXC Chemokine Ligand 12 Endocrinology, July 1, 2005; 146(7): 3005 - 3017. [Abstract] [Full Text] [PDF]

				V. Cingel-Ristic, J. W. van Neck, J. Frystyk, S. L. S. Drop, and A. Flyvbjerg Administration of Human Insulin-Like Growth Factor-Binding Protein-1 Increases Circulating Levels of Growth Hormone in Mice Endocrinology, September 1, 2004; 145(9): 4401 - 4407. [Abstract] [Full Text] [PDF]

				J. G. Miquet, A. I. Sotelo, A. Bartke, and D. Turyn Suppression of Growth Hormone (GH) Janus Tyrosine Kinase 2/Signal Transducer and Activator of Transcription 5 Signaling Pathway in Transgenic Mice Overexpressing Bovine GH Endocrinology, June 1, 2004; 145(6): 2824 - 2832. [Abstract] [Full Text] [PDF]

				K. Iida, J. P. Del Rincon, D.-S. Kim, E. Itoh, R. Nass, K. T. Coschigano, J. J. Kopchick, and M. O. Thorner Tissue-Specific Regulation of Growth Hormone (GH) Receptor and Insulin-Like Growth Factor-I Gene Expression in the Pituitary and Liver of GH-Deficient (lit/lit) Mice and Transgenic Mice that Overexpress Bovine GH (bGH) or a bGH Antagonist Endocrinology, April 1, 2004; 145(4): 1564 - 1570. [Abstract] [Full Text] [PDF]

				K. T. Coschigano, A. N. Holland, M. E. Riders, E. O. List, A. Flyvbjerg, and J. J. Kopchick Deletion, But Not Antagonism, of the Mouse Growth Hormone Receptor Results in Severely Decreased Body Weights, Insulin, and Insulin-Like Growth Factor I Levels and Increased Life Span Endocrinology, September 1, 2003; 144(9): 3799 - 3810. [Abstract] [Full Text] [PDF]

				R. J. M. Ross, K. C. Leung, M. Maamra, W. Bennett, N. Doyle, M. J. Waters, and K. K. Y. Ho Binding and Functional Studies with the Growth Hormone Receptor Antagonist, B2036-PEG (Pegvisomant), Reveal Effects of Pegylation and Evidence That It Binds to a Receptor Dimer J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1716 - 1723. [Abstract] [Full Text]

				A. Bartke, V. Chandrashekar, D. Turyn, R. W. Steger, L. Debeljuk, T. A. Winters, J. A. Mattison, N. A. Danilovich, W. Croson, D. R. Wernsing, et al. Effects of Growth Hormone Overexpression and Growth Hormone Resistance on Neuroendocrine and Reproductive Functions in Transgenic and Knock-Out Mice Experimental Biology and Medicine, November 1, 1999; 222(2): 113 - 123. [Abstract] [Full Text]

				F. P. Dominici, D. Cifone, A. Bartke, and D. Turyn Alterations in the early steps of the insulin-signaling system in skeletal muscle of GH-transgenic mice Am J Physiol Endocrinol Metab, September 1, 1999; 277(3): E447 - E454. [Abstract] [Full Text] [PDF]